Business Wire

TX-TQ-DELTA

30.5.2019 00:13:05 CEST | Business Wire | Press release

Share
Significant Patent Win for TQ Delta

TQ Delta LLC, a technology development and licensing firm, secured another favorable judgment last week when a Delaware federal jury found that 2Wire Inc. infringed three of TQ Delta’s patents related to Digital Subscriber Line (“DSL”) technology. 2Wire is a subsidiary of ARRIS Solutions, which was recently acquired by CommScope Inc.

TQ Delta’s patents cover important memory sharing capabilities for DSL modems and central office equipment, among other inventions. TQ Delta notes that these inventions are widely employed not just in the United States, but around the world.

This ruling represents another victory for TQ Delta’s ongoing licensing business. Earlier this year, the High Court of Justice of England and Wales also found in favor of TQ Delta on another patent from its deep portfolio of DSL inventions. The UK Proceeding against ZyXEL Communications UK Ltd and its Danish parent company, ZyXEL Communications A/S (both subsidiaries of Unizyx Holding Corporation) found TQ Delta’s European Patent (UK) 1 453 268 valid and infringed, as well as essential to the standards for ADSL2 and VDSL2. The Court granted an immediate injunction and award of costs against the ZyXEL defendants. ZyXEL defendants have appealed some elements of the judgment and that appeal is pending. TQ Delta’s worldwide portfolio spans a broad range of standard essential patents (“SEPs”) and non-SEPs that are central to key broadband network technologies. In addition to validation by courts in the US and UK, TQ Delta has successfully licensed its technology to key market participants.

The most recent verdict was announced on May 23 following a nearly four-day trial in the United States District Court for the District of Delaware. After deliberation, the eight-member jury returned a favorable verdict on all eleven counts, finding that 2Wire infringed U.S. Patent nos. 7,836,381, 7,844,882 and 8,276,048, that those patents were not obvious over prior art, and that two certificates of correction were not invalid.

“We are pleased with the jury’s decision affirming the strength and importance of our portfolio of inventions, which are the culmination of years of investment in standards development and communications technologies,” said Abha Divine, Managing Director of TQ Delta.

TQ Delta has supported continued development of DSL markets by maintaining a longstanding business strategy designed to ensure advancements in the technology. “The TQ Delta portfolio and continued investment in the field contributes to the past, present, and future of high-speed DSL connections around the world. We have already licensed several companies to practice the important inventions under our DSL portfolio and will continue to seek to license others through business negotiations,” said Divine.

TQ Delta was represented by McAndrews, Held, and Malloy, Ltd., a firm specializing in intellectual property prosecution, counselling, and dispute resolution.

Lead trial attorney, Peter McAndrews, explained that “The Defendant’s strategy was to trivialize the important inventions at issue. We are pleased that the jury vindicated the inventors’ hard work and our client’s commitment to innovation.”

TQ Delta maintains a sizable patent portfolio for digital communication technology, including DSL.

About TQ Delta

TQ Delta is a technology development and licensing company aimed at providing needed solutions for the communications industry and beyond. The company’s technical investments span nearly two decades of contributions and innovation in the field of communications. TQ Delta’s technologies are used in leading products and services worldwide spanning broadband communications and media distribution. For more information, visit http://www.tqdelta.com .

Contact:

Scott Krady Magnitude, Inc. scott@magnitudegrowth.com

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye